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Summary
Objective The objective of this study was to evaluate 
adherence and causes for non-adherence to antihyper-
tensive therapy in Austrian patients. A special focus was 
placed on social parameters and behavioural theories.
Methods Patients were invited via advertisements 
in community pharmacies in Austria to complete an 
online survey. Inclusion criteria were an age of 18 years 
or older, a diagnosis of arterial hypertension and a cur-
rent prescription of antihypertensive medication. Adher-
ence was measured by the four-item Morisky scale. 
Non-adherence was defined by at least one point in the 
Morisky scale. Several demographic, social and behav-
ioural parameters were analysed as potential co-vari-
ables associated with adherence.
Results A total of 323 patients completed the online 
survey, of which 109 (33.7 %) met the criteria for non-
adherence. In a multivariable model, self-efficacy and 
age were associated with adherence, whereas intention 
and barriers were linked to non-adherence; 56 patients 
(17.3 %) were classified as intentionally non-adherent.
Conclusion This study demonstrates that non-adher-
ence affects an important proportion of patients in the 
treatment of arterial hypertension. Young age was a par-
ticularly important risk factor for non-adherence, and 
this patient population is, therefore, in need of special 
attention. Modifiable risk factors were identified that 
could help improving the treatment of arterial hyperten-
sion and potentially other chronic conditions.
Keywords Adherence  · Arterial hypertension · Medica-
tion
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Introduction
Over the past decades, important progress in medi-
cal and pharmaceutical sciences led to the develop-
ment of new efficacious treatments for diverse chronic 
conditions. However, the ultimate impact of any drug 
treatment—often measured as the effectiveness—also 
depends on the patients’ adherence to it. Treatments 
with high efficacy in clinical trials may turn out to be 
only moderately effective due to incomplete medica-
tion adherence with recommended dosing regimens in 
real-world settings. Non-adherence was therefore iden-
tified as a major public health problem by constituting 
a barrier to the effective, safe and cost-effective use of 
drugs [1]. Conclusively, the World Health Organization 
(WHO) reported non-adherence as a worldwide medi-
cal problem associated with excess morbidity, mortal-
ity and unnecessary costs [2]. WHO defined adherence 
‘as the extent to which a person’s behaviour—taking 
medication, following a diet and/or executing lifestyle 
changes—corresponds with agreed recommendations 
from a health care provider’ [2]. Taking this further, 
Vrijens et al. [3] recently introduced a new taxonomy 
for describing and defining adherence to medication. 
It was proposed to uniformly use the term ‘medication 
adherence’, which was defined as ‘the process by which 
patients take their medications as prescribed, composed 
of initiation, implementation and discontinuation’. In 
accordance with this new taxonomy, the term ‘medi-
cation adherence’ will be used throughout this manu-
script. In arterial hypertension—defined as a systolic 
blood pressure of 140 mmHg or higher and/or a diastolic 
blood pressure of 90 mmHg or higher—lack of medica-
tion-adherence to prescribed medicines is a major rea-
son for unsatisfying therapeutic outcomes and therefore 
a major challenge [4]. Similar to other chronic condi-
tions, including diabetes and overweight, a main reason 
for problems in patients’ adherence is the asymptomatic 
nature of the disease. Other previously reported factors 
contributing to non-adherence include the long-term 
disease course of hypertension and thus the necessity 
for lifelong treatment and multiple daily dosing [5, 6].
Improving the adherence to therapeutic regimens 
could substantially improve therapeutic outcomes, espe-
cially in high-income countries, where effective drugs 
are widely available for everybody. It may prove most cost 
effective to increase the effectiveness of already licensed 
drugs by improving medication adherence rather than 
focussing on developing further new therapeutic prod-
ucts. A better understanding of causes of non-adherence 
is, however, necessary to ultimately improve effective-
ness of current drugs. Thus, the aim of this study was to 
evaluate adherence to long-term medication in Austria 
and determine its causes, with a special focus on social 
parameters and behavioural theories.
Methods
Data presented in this article stem from the European 
Union (EU) funded project ‘Ascertaining Barriers for 
Compliance: policies for safe, effective and cost-effective 
use of medicines in Europe’ (ABC). Cumulative data for 
the entire European cohort were published in June 2012 
in the Final Study Report of the ABC Project and in ‘Value 
in Health’ (in press). This manuscript describes in detail 
findings of this survey restricted to Austria.
Patients were recruited via advertisements (posters 
and printed material) in community pharmacies across 
Austria, which were randomly selected from a list pro-
vided by the national prescription pricing authority. A 
total of 1272 pharmacies were contacted. Patients were 
eligible if they were 18 years of age or older, had a diag-
nosis of arterial hypertension, were currently prescribed 
medication against arterial hypertension and were self-
responsible for drug administration. Exclusion criteria 
were lack of consent, presence of a self-reported psychi-
atric condition and living in a nursing home or similar 
facility. The questionnaire was completed via a web-
based survey tool provided by SurveyMonkey.com.
Measuring adherence
In this study, adherence was measured by the four-item 
Morisky Medication Adherence Scale (MMAS-4). The 
MMAS-4 is the most frequently used questionnaire mea-
suring adherence to medication [7]. This scale, originally 
designed to evaluate medication adherence in hyperten-
sive patients, has been validated and found to be reliable 
in a variety of medication adherence studies [8].
Patients were categorized as non-adherent if they 
answered one or more question of the MMAS-4 with 
‘yes’. They were classified as intentionally non-adherent 
when either item 3 or 4 or both were answered with ‘yes’ 
(see also Table 1). Items 1 and 2 of the MMAS-4 (i.e. ‘Do 
you ever forget to take your high blood pressure medi-
cine?’ and ‘Do you ever have problems remembering to 
take your blood pressure medicine?’) are related to the 
implementation of the dosing regimen and are more 
non-intentional whereas items 3 and 4 (i.e. ‘When you 
feel better, do you sometimes stop taking your high blood 
pressure medicine?’ and ‘Sometimes, if you feel worse 
when you take your blood pressure medicine, do you 
stop taking it?’) are related to treatment discontinuation 
and are intentional.
Measurement of variables and instruments used
The Stanford Self-Rated Health Scale was used to mea-
sure health status; the Revised Life Orientation Test was 
used to determine dispositional optimism [9]; the Beliefs 
about Medicines Questionnaire (BMQ-S11) was applied 
to evaluate beliefs about medicine [10]; and to measure 
attitudes, normative beliefs, barriers, facilitators, inten-
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Variable (% missing data) Median (25th–75th percen-
tile) or absolute numbers 
(% of overall population)
Age (0 %) 62 years (51–69 years)
Sex (0 %)
 Male 178 (55.1 %)
 Female 145 (44.9 %)
Civil Status (2.2 %)
 Married 209 (64.7 %)
 Single/divorced/widow 107 (33.1 %)
Education (2.8 %)
 Primary/secondary 120 (37.2 %)
 Higher than primary/secondary 194 (60.1 %)
Employment (1.5 %)
 Working/student 119 (36.8 %)
 Retired/unemployed 199 (61.6 %)
Number of medical conditions, median 
(1.2 %)
2 (1–3)
Number of medicines, median (1.2 %) 4 (2–6)
Number of tablets per day, median (2.8 %) 4 (2–7)
Dosage frequency (0.9 %)
 Once daily 114 (35.3 %)
 Two times daily 110 (34.1 %)
 Three times daily 96 (29.7 %)
  More than three times daily 0 (0 %)
Self reported health status (0.6 %)
 Poor 23 (7.1 %)
 Fair 96 (29.7 %)
 Good 128 (39.6 %)
 Very good/excellent 74 (22.9 %)
Number of items on last prescription, 
median (8.7 %)
4 (2–6)
Do you pay for prescription (0.9 %)
 No 26 (8.0 %)
 Yes, prescription charge 282 (87.3 %)
 Yes, full cost 12 (3.7 %)
Affordability problem (0.9 %)
 No 231 (71.5 %)
 Yes 89 (27.6 %)
Use of cost coping strategies, mean (3.1 %) 0.9585
Optimism—life orientation test (0 = low, 
24 = high; 9.0 %)
15 (13–18)
Necessities of medicines (5 = low, 25 = high; 
8.6 %)
19 (16.75–22)
Concerns about medicines (6 = low, 
30 = high; 10.8 %)
15 (12–19)
Attitudes—theory of planned behaviour 
(7 = low, 35 = high; 12.3 %)
28 (25–32)
Normative beliefs—theory of planned behav-
iour (3 = low, 15 = high; 12.3 %)
15 (12–15)
Barriers—theory of planned behaviour 
(1 = low, 5 = high; 10.2 %)
1 (1–3.75)
Table 1 Demographic data and missing data for overall study 
population (n = 323)
Variable (% missing data) Median (25th–75th percen-
tile) or absolute numbers 
(% of overall population)
Facilitators—theory of planned behaviour 
(3 = low, 15 = high; 13.6 %)
8 (5–11)
Intention—theory of planned behaviour 
(2 = low, 10 = high; 10.2 %)
10 (9–10)
Self efficacy—theory of planned behaviour 
(2 = low, 10 = high; 7.4 %)
8 (6–10)
Practitioner (7.4 %)
 General practitioner/family physician 163 (50.5 %)
 Other 136 (42.1 %)
Gender of practitioner (10.2 %)
 Female 114 (35.3 %)
 Male 176 (54.5 %)
EUROPEP satisfaction with practitioner 
(17 = low, 85 = high; 18.9 %)
70 (62–79)
EUROPEP satisfaction with practice (6 = low, 
30 = high; 16.1 %)
24 (21–29)
BRIGHT barriers (0 = low, 60 = high; 45.8 %) 5 (1–8.5)
BRIGHT social support (0 = low, 28 = high; 
13.0 %)
2 (0–4)
BIPQ
 Illness consequences (8.0 %) 5 (2–8)
 Illness timeline (8.7 %) 10 (8–10)
 Personal control (8.0 %) 7 (4–8)
 Treatment control (9.0 %) 9 (7–10)
 Identity (9.6 %) 5 (2.75–7)
 Concern about illness (9.3 %) 5 (3–8)
 Illness coherence (10.8 %) 8 (6–10)
 Emotional representations (9.6 %) 4 (2–6)
Income (11.5 %)
 Salaries/wages 93 (28.8 %)
 Pensions/benefits/others 193 (59.8 %)
Total Income (deciles; 9.0 %)
 1–4 96 (29.7 %)
 5–7 103 (31.9 %)
 8–10 57 (17.6 %)
 Not willing to provide 38 (11.8 %)
Income perception (8.0 %)
 Comfortable 65 (20.1 %)
 Coping 141 (43.7 %)
 Difficult/very difficult 54 (16.7 %)
 Not willing to provide 37 (11.5 %)
Ease of borrowing (8.7 %)
 Very difficult, quite difficult 122 (37.8 %)
 Neither easy nor difficult 85 (26.3 %)
 Quite easy, very easy 38 (11.8 %)
 Not willing to provide 50 (15.5 %)
EUROPEP European Task Force on Patient Evaluation in General Practice 
questionnaire, BRIGHT Building Research Initiative Group: Chronic Illness 
Management and Adherence in Transplantation, BIPQ Brief Illness Percep-
tion Questionnaire
Table 1 (Continued) 
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fore classified as non-adherent; 56 patients (17.3 %) 
were classified as intentionally non-adherent. In detail, 
84 (26.0 %) participants answered item 1 of the MMAS-4 
with yes, 33 (10.2 %) item 2, 40 (12.4 %) item 3 and 33 
(10.2 %) participants item 4.
Factors influencing non-adherence
In univariate analysis, young age was associated with 
non-adherence. The rate of non-adherence was also sig-
nificantly higher in working patients or students com-
pared with retired or unemployed ones. Conversely, 
adherent patients were prescribed a higher number of 
different drugs (p = 0.001), tablets per day (p = 0.008) and 
had more items on the last prescription (p = 0.028).
Patients classified as adherent had a high score in the 
perceived necessity section of the Beliefs About Medicine 
Questionnaire, the attitude, normative beliefs, inten-
tion and self efficacy section of the Theory of Planned 
Behaviour Questionnaire and the perceived illness con-
sequences, illness timeline, personal control, treatment 
control and illness coherence part of the BIPQ. Satisfac-
tion with the treating practitioner and his practice were 
significantly higher in adherent patients. In contrast, 
the use of cost coping strategies and a high score in the 
perceived barriers section of the BRIGHT questionnaire 
were associated with non-adherence.
tion and self-efficacy, a theory of planned behaviour 
(TPB) questionnaire was used. TPB is a theory in psychol-
ogy about the link between beliefs and behaviour [11]. 
A questionnaire of the European Task Force on Patient 
Evaluation in General Practice was used to measure satis-
faction with the practitioner and her/his practice [12]; the 
Building Research Initiative Group: Chronic Illness Man-
agement and Adherence in Transplantation (BRIGHT) 
was used for barriers and social support [13, 14]; and the 
Brief Illness Perception Questionnaire (BIPQ) was applied 
to assess parameters of illness perception [15].
Ethical considerations
Ethical approval was obtained by the national ethics 
committee in Austria (590/2011). Participants provided 
informed consent by checking a box in the online survey 
to confirm that they had read and understood all par-
ticipant information. Access to the survey was denied 
if the box was not checked. SurveyMonkey®, where the 
questionnaire responses were stored initially, guaran-
teed data safety. SurveyMonkey® has signed up to the Safe 
Harbor agreement. This agreement was created to enable 
the transfer of ‘personal data’ between the EU and USA 
following the introduction of the EU’s Data Protection 
Directive (1995). SurveyMonkey® was asked in written to 
completely delete survey data from its servers after the 
termination of the survey.
Data analysis
The primary outcome of this study was the estimation 
of the percentage of non-adherent patients defined as 
patients having answered ‘yes’ to at least one of the four 
items of the Morisky questionnaire. For binominal vari-
ables, a Fisher’s test was applied to calculate differences 
in distribution between adherent and non-adherent 
patients. For continuous variables, a Mann–Whitney test 
was computed. Binary logistic regression analysis was 
performed to compute a multivariate model including 
parameters with a significant difference in distribution 
between adherent and non-adherent patients. Complete 
case analysis was used. Normal approximation of the 
binomial distribution was used to derive 95 % confidence 
intervals. Statistical analysis was performed with ‘R’, ver-
sion 3.0.2.
Results
A total of 323 participants completed the questionnaire; 
178 (55.1 %) were men and 145 (44.9 %) women. Median 
age was 62 years (25th– 75th percentile: 51–69 years; 
range: 25–89 years). For more demographic data, see 
Table 1.
In the overall study population, 109 (33.7 %) partici-
pants had a Morisky score of 1 or more and were there-
Table 2 Multivariable model investigating association be-
tween various variables and non-adherence
Variable OR 95 % CI p-Value
Age 0.94 0.89–0.99 0.022
Number of medicines 0.93 0.67–1.25 0.622
Number of tablets per day 1.00 0.85–1.13 0.983
Employment status 1.96 0.56–7.32 0.299
Number of medical conditions 0.96 0.64–1.37 0.829
Use of coping strategies 0.95 0.77–1.14 0.619
Necessities (BMQ) 0.92 0.79–1.07 0.303
Attitudes (TPB) 0.97 0.88–1.08 0.620
Normative believes (TPB) 0.94 0.79–1.11 0.458
Self efficacy (TPB) 0.66 0.52–0.83 < 0.001
Intention (TPB) 1.44 1.04–2.16 0.044
Illness consequences (BIPQ1) 0.91 0.77–1.08 0.282
Illness timeline (BIPQ2) 0.95 0.74–1.21 0.661
Personal control (BIPQ3) 0.99 0.82–1.19 0.897
Treatment control (BIPQ4) 1.08 0.80–1.46 0.614
Illness coherence (BIPQ7) 0.92 0.75–1.12 0.395
Satisfaction of practitioner 1.03 0.97–1.09 0.399
Satisfaction with practice 1.05 0.91–1.22 0.486
Barriers (BRIGHT) 1.12 1.02–1.23 0.025
BMQ Beliefs about Medicines Questionnaire, TPB theory of planned 
behaviour questionnaire, BRIGHT Building Research Initiative Group: Chronic 
Illness Management and Adherence in Transplantation, BIPQ Brief Illness 
Perception Questionnaire, OR odds ratio, CI confidence interval
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the manner necessary to solve a problem become more 
inclined to do so and feel more committed to their deci-
sions and behaviours [22]. Self efficacy can be influenced 
by a person’s own experience, the experiences of others, 
social persuasion and by their psychological status [23]. 
Also, barriers including perceived or actual side effects of 
drugs or forgetfulness should be specifically addressed 
in all patients with hypertension to optimize therapeu-
tic outcomes. This also shows that personal beliefs and 
social influences are more important for adherence than 
the clinical situation or factors attributable to the dis-
ease itself. Paradoxically, we also found high behavioural 
intention to be associated to non-adherence. This finding 
stands in contrast to literature [24], and we speculate that 
it might be an artefact of statistical analyses, especially 
because intention was already very high in the overall 
study population (median 10 out of 10 points).
Our results also show the crucial role of allowing 
enough time in personal communications between the 
practitioner and patients to make interventions possible 
and successful. Such risk factors can be influenced by a 
range of interventions. Self-efficacy might be increased 
by programs such as the herz.leben program, which was 
established in Styria, Austria. This programme provides 
structured training for patients on several aspects of the 
treatment and control of the disease (e.g. adequate nutri-
tion, physical exercise, blood measurement training) and 
was shown to significantly decrease blood pressure and 
the risk of a cardiovascular event [25].
Limitations of this study included the way of data 
acquisition possibly leading to a selection bias in the 
study population. Questionnaires and responses were 
provided via Internet leading to the impossibility to 
confirm diagnoses or responses. Importantly, patient 
groups without Internet access were most likely under-
represented in this survey. The so-called self-serving 
bias, defined as the distortion of cognition of percep-
tion to maintain self-esteem, might have confounded 
our results, and the impact of non-responders was not 
assessable during this survey. However, the anonymity of 
this survey may also be regarded as strength, as respond-
ers are less likely to conceal non-adherence compared 
with personal interviews.
In summary, this study reports a high proportion 
of non-adherence to antihypertensive medication in 
Austria, but identifies modifiable variables influencing 
adherence. This survey may provide important insights 
for the treatment of arterial hypertension and other 
chronic conditions. Future studies should evaluate spe-
cific interventions to improve adherence to therapeutic 
regimens. This could help to ameliorate effectiveness 
and efficiency of existing drugs.
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In a multivariable model, older age (odds ratio (OR): 
0.94, 95 % confidence interval (CI): 0.89–0.99; p = 0.02) 
and self-efficacy (i.e. the personal sense of control; TPB); 
OR: 0.66, 95 % CI: 0.52–0.83; p < 0.001) were associated 
with adherence, whereas intention (TPB; OR: 1.44, 95 % 
CI: 1.04–2.16; p = 0.04) and perceived barriers (BRIGHT; 
OR: 1.11, 95 % CI: 1.02–1.23; p = 0.02) were linked to non-
adherence (see Table 2).
Intentional non-adherence
Intentional non-adherence was significantly more fre-
quent in participants reporting regular employment or 
students than in retired or unemployed (15.0 vs. 33.7 %; 
p = 0.01). Use of cost coping strategies was associated 
with intentional non-adherence (Mann–Whitney U: 
p = 0.048). Scores in the variables attitudes, intention, 
self-efficacy and normative believes (TPB) and illness 
timeline and treatment control (BIPQ) were lower in 
patients classified as intentionally non-adherent. Also, 
a high score in perceived barriers (BRIGHT) was signifi-
cantly associated with intentional non-adherence. Due 
to the small case numbers, multivariable analysis was 
omitted.
Discussion
Non-adherence to antihypertensive medication was 
33.7 % in our patient population. These data therefore 
demonstrate a clear need for improvement of patient care 
even in high-income countries, where universal access 
to healthcare is guaranteed. The observed proportion is 
considerably higher than for other medical conditions 
with a more symptomatic disease course including mul-
tiple sclerosis or follow-on therapy after acute coronary 
syndrome [16, 17]. However, other European countries 
had considerably higher proportions of non-adherence, 
for example, accounting for up to 70 % of patients in Hun-
gary [18].
In our multivariable analysis, we identified four risk 
factors significantly influencing the adherence to antihy-
pertensive medication.
Young age was shown to be associated with non-
adherence. Although this is a non-modifiable factor, 
young patients may require specially tailored informa-
tion or advice to improve adherence. This may be of 
particular importance because young patients are most 
likely to benefit from improved adherence to antihyper-
tensive drugs, in that they can decrease the cardiovascu-
lar risk of a long-term hypertensive disease.
Among the modifiable risk factors low self-efficacy 
(TPB), high intention (TPB) and high perceived barriers to 
medication adherence (BRIGHT) were identified as pre-
dictors for non-adherence. Self-efficacy is the personal 
sense of behavioural control, and its crucial importance 
in several different settings was shown previously [19–21]. 
People who believe that they have the ability to behave in 
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